drugset / Trial / NCT05384210
Effect of Milnacipran / Gabapentin in Fibromyalgia
RandomizedParallel-groupOpen-labelSupportive care
Summary
Gabapentin and milnacipran (MLN) show strong evidence of reduced pain, increased sleep, and improvement in the quality of life in fibromyalgia (FM) patients. Most FM trials focus primarily on pain reduction with monotherapy. Polypharmacy is commonly used, but supportive evidence is limited. The gabapentin-MLN combined therapy may be more effective in female patients with FM than their monotherapy.
Timeline
- Start
- 2022-06
- Primary completion
- 2023-10
- Completion
- 2023-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gabapentin | Small molecule | 800 mg | — |
| Comparator | Milnacipran | Other / unclassified | 100 mg | — |